Latest Manufacturing Processes News

Entropy Neurodynamics has partnered with BioCina to establish GMP manufacturing for its intravenous psilocin formulation TRP-8803, a critical step toward late-stage clinical trials and commercialisation.

Barramundi Limited’s portfolio delivered a 2.2% gross return in July, outpacing the S&P/ASX200 hedged benchmark, driven by strong performances in healthcare and financials alongside strategic portfolio adjustments.

NeuroScientific Biopharmaceuticals (ASX:NSB) has locked in a key FDA Pre-IND meeting for late August, advancing its Phase 2 trial plans for StemSmart™ targeting refractory Crohn’s disease in the US and Australia.

EBR Systems marked a commercial milestone with over 100 WiSE CRT implants and secured purchasing agreements with three major US healthcare networks. The company is progressing toward Medicare coverage and scaling manufacturing, supported by a near-complete A$150 million capital raise.

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial stays on track for November topline results, buoyed by strong open-label extension enrolment and aligned EMA-FDA regulatory advice. A new antidepressant study publication and fresh patents add momentum, supported by a $16.7 million cash runway to mid-2027.

AdAlta has completed a key US$1 million milestone payment securing rights to its lead CAR-T therapy EW-001 outside Greater China, progressed Australian manufacturing with first runs expected late 2026, and is preparing for a critical pre-IND meeting with the US FDA.

Critical Resources (ASX:CRR) spotlighted its multi-commodity pipeline and breakthrough battery cooling technology at the July 2026 TechKnow Invest Roadshow, highlighting exploration progress and exclusive global licensing deals.

Amaero Inc. capped FY2026 with a record A$18.1 million revenue, expanded its production capacity, and landed a A$6.5 million US Department of War contract to develop alternative refractory alloy powders.

Noxopharm reported significant progress in its Sofra technology, highlighting enhanced cancer drug potential and preparations for a US FDA clinical trial, while managing tight cash reserves.

Cadoux Ltd and the SAFELOOP consortium have surpassed key performance and recycling targets in lithium-ion battery development, marking a world-first in commercial-scale use of recycled active materials enhanced by Cadoux's premiumHPA®. This breakthrough advances the pathway to gigafactory production and strengthens Cadoux's position in the EV battery supply chain.

Entropy Neurodynamics has expanded its global intellectual property portfolio with a South African patent for psilocybin-based fibromyalgia treatment, covering broad therapeutic methods and extending protection to 2043.

Mesoblast has completed treatment of 300 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain due to degenerative disc disease, with topline results expected mid-2027.